MS relapse rates similar between anti-CD20 mAbs and switching to fumaratesJune 9, 2023Multiple Sclerosis
Ozanimod for relapsing MS shows long-term safety, efficacy with age differencesJune 8, 2023Multiple Sclerosis
Multiple changes in NMOSD treatment for nonmedical reasons tied to poorer outcomesJune 6, 2023Multiple Sclerosis
Raising Awareness for Managing Disease-Modifying Therapies in Aging Persons With Multiple Sclerosis April 21, 2023Multiple Sclerosis
